论文部分内容阅读
目前,抗逆转录病毒的治疗虽然已经有了显著进展,但寻找价格低廉、活性更强、不易耐药的抗HIV药物研发工作仍在继续。目前国内外针对HIV复制周期进入、融合、整合以及成熟过程中新靶点的研究成为热点。文中对药物进入/融合抑制剂(包括病毒吸附抑制剂、病毒辅助受体抑制剂、病毒融合抑制剂)、整合酶抑制剂和成熟抑制剂的作用机制和特点进行了综述,并且,介绍了2008年新上市的非核苷类逆转录酶抑制剂intelence(etravirine)的特点。
Although antiretroviral therapy has made significant progress, research and development on anti-HIV drugs that are cheaper, more active and less drug-resistant continue to be conducted. At present, the research on the new target of entering, integrating, integrating and maturing the HIV replication cycle has become a hot spot at home and abroad. The mechanisms and characteristics of drug entry / fusion inhibitors (including viral adsorption inhibitors, virus-assisted receptor inhibitors, viral fusion inhibitors), integrase inhibitors and maturation inhibitors are reviewed in this paper The characteristics of the new listing of nonnucleoside reverse transcriptase inhibitors intelence (etravirine).